Hermetica Superfood Encyclopedia
Artemisia absinthium contains absinthin and thujone compounds that demonstrate anti-inflammatory effects through TNF-alpha suppression. Clinical trials show significant inflammatory marker reduction and steroid-sparing effects in Crohn's disease patients.
Origin & History
Artemisia absinthium, commonly known as wormwood, is a perennial herb native to Europe, Asia, and North Africa, belonging to the Asteraceae family. The aerial parts of the plant are harvested and typically extracted using ethanol or methanol solvents via maceration or percolation methods. It contains bioactive compounds including thujone and absinthin from the sesquiterpene lactone class.
Scientific Research
Human clinical evidence is limited primarily to inflammatory bowel disease, with a controlled trial showing TNF-alpha reduction in Crohn's patients (PMID: 19962291) and a double-blind RCT (n=40) demonstrating steroid-sparing effects (PMID: 17240130). A small pilot trial investigated effects on IgA nephropathy proteinuria using thujone-free extracts (PMID: 20843592), though most other evidence remains preclinical.
Preparation & Dosage
Clinically studied dosage for Crohn's disease: 1500 mg/day of dried herb (taken as 3x500 mg capsules) for 6 weeks. Thujone-free extracts were used in kidney disease studies (specific dose not detailed). No standardization percentages specified in human trials. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Artemisia absinthium (wormwood) is a non-nutritive bitter herb consumed in trace culinary/medicinal quantities, not a significant source of macronutrients or conventional micronutrients. Key bioactive compounds dominate its profile: Sesquiterpene lactones: absinthin and artabsin are the primary bitter principles at approximately 0.15–0.40% dry weight, responsible for digestive and anti-inflammatory effects. Thujone (monoterpene ketone): the most toxicologically significant compound, present as alpha-thujone and beta-thujone in the essential oil at 3–12 mg/kg in regulated preparations; EU regulations cap thujone in food products at 10 mg/kg (foods) and 35 mg/kg (alcoholic beverages). Essential oil content: 0.2–1.5% of dry herb weight, composed primarily of thujone, chamazulene (anti-inflammatory, ~2–5% of oil), sabinene, and beta-pinene. Flavonoids: artemetin, eupatilin, and quercetin derivatives present at approximately 0.5–1.2% dry weight; quercetin contributes to TNF-alpha suppression observed in clinical trials. Phenolic acids: chlorogenic acid and caffeic acid derivatives at ~0.3–0.8% dry weight. Azulenes: chamazulene formed during steam distillation contributes anti-inflammatory properties. Lignans and coumarins present in minor quantities (<0.1%). Protein content negligible (<1% dry weight). Fiber: moderate insoluble fiber in whole herb form (~15–20% dry weight) but irrelevant at medicinal doses (typically 1–3g dried herb or standardized extracts). Bioavailability notes: absinthin and artabsin are poorly water-soluble but extracted effectively in ethanol-based preparations; flavonoids show moderate bioavailability enhanced by the herb's bitter-induced bile secretion. Thujone bioavailability is high via lipid-soluble pathways, necessitating strict dosage control to avoid neurotoxicity.
How It Works
Artemisia absinthium's bioactive compounds absinthin and thujone suppress pro-inflammatory cytokines, particularly TNF-alpha, through inhibition of NF-κB pathway activation. The sesquiterpene lactones in the plant modulate T-cell responses and reduce inflammatory mediator production in intestinal tissues.
Clinical Evidence
A controlled trial (PMID: 19962291) demonstrated significant TNF-alpha reduction from 24.5 to 8.0 pg/ml in Crohn's disease patients after 6 weeks of treatment. Double-blind RCT evidence shows steroid-sparing effects, allowing maintenance of remission with reduced corticosteroid doses. The clinical evidence is limited but promising, with small sample sizes requiring larger confirmatory studies.
Safety & Interactions
Thujone content raises concerns about neurotoxicity at high doses, potentially causing seizures and hallucinations. Contraindicated during pregnancy and breastfeeding due to abortifacient properties and thujone transfer. May interact with anticonvulsant medications and should be avoided by individuals with epilepsy. Long-term use may cause digestive upset and liver stress.
Also Known As
Frequently Asked Questions
What is the active compound in artemisia absinthium?
How much does artemisia absinthium reduce inflammation?
Is artemisia absinthium safe for long-term use?
Can artemisia absinthium replace steroids for Crohn's disease?
What dosage of artemisia absinthium is effective?
Does artemisia absinthium interact with immunosuppressant medications used for Crohn's disease?
Who is most likely to benefit from artemisia absinthium supplementation?
What is the evidence quality for artemisia absinthium's effects on inflammatory bowel disease?
Conditions This May Help
This profile shares topic or mechanism tags with the health areas below. The links open provisional public-profile indexes; association does not establish a benefit or clinical recommendation.
Or jump to the curated Inflammation & Joint Health Profile Collection → a provisional discovery list with review-state disclosure.
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.